Blog

Markus Kosch: How do we unlock the full potential of precision medicine – for all patients?

Markus Kosch/LinkedIn

Jul 17, 2025, 10:03

Markus Kosch: How do we unlock the full potential of precision medicine – for all patients?

Markus Kosch, Head Oncology Europe and Canada at Daiichi Sankyo Europe GmbH, shared a post on LinkedIn:

“How do we unlock the full potential of precision medicine – for all patients? That was the guiding question at last week’s genomDE symposium in Berlin, where researchers, policymakers, patient advocates, and industry leaders came together to explore opportunities and roadblocks along the path to more personalised care.

I was grateful to contribute to the discussion, focusing on biomarker-driven innovative therapeutic approaches – enabling patient-centred oncology.

Across all panel discussions, one key theme stood out: innovation alone is not enough. Science is evolving fast – we need to ensure that our regulatory systems are also adapting at the same pace, to make sure that personalised treatments reach patients quickly as well.

In particular, we need:

A robust data infrastructure that integrates genomic information and clinical data
Regulatory alignment to enable faster, smarter trials
A shared commitment to making precision care universally accessible

It was truly encouraging to see so many committed voices working towards these goals – and to be reassured that science moves faster when we work closely together.

Thank you to all organisers, speakers, and patients for an inspiring exchange. What do you see as the most important step to make personalised treatments become a reality for all patients?

Photo credit: TMF e.V. / Volkmar Otto.”

More posts featuring Markus Kosch.